FDA Approves Phase II Kidney Cancer Therapy Study
Go back to FDA Approves Phase II Kidney Cancer Therapy Study| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 12.04 +0.75 (6.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.29 | 52 Week High | $2.18 | |||
| Open | $12.20 | 52 Week Low | $0.30 | |||
| Day High | $12.23 | P/E | N/A | |||
| Day Low | $11.67 | EPS | $-3.32 | |||
| Volume | 413,431 | |||||
